Results 21 to 30 of about 12,115,436 (205)
The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events [PDF]
, 2021 Hydroxychloroquine is an established therapy for several rheumatological disorders, and very recently it has been proposed as a possible treatment for the new coronavirus disease 2019 even if recent randomised trials did not prove any benefit.
Alaibac, Mauro +15 more
core +1 more source
Profile of adverse events (AE) based on initial dose of enzalutamide.
, 2021 Profile of adverse events (AE) based on initial dose of enzalutamide.
Jun Miki (11512692) +10 more
core +1 more source
Ciclosporin A in ophthalmology: A systematic review
Kerala Journal of Ophthalmology, 2019 Aim: To systematically analyse data from randomized controlled trials of topical Ciclosporin with the aim of assessing the uses and effectiveness of Ciclosporin in different conditions, optimal dosage and adverse effect profile. Methods: 24 RCTs that had
Kaberi Biswas Feroze
doaj +1 more source
National Journal of Physiology, Pharmacy and Pharmacology, 2023 Background: Coronavirus 2019 was declared as a pandemic by the World Health Organization in March 2020. Bereft of specific treatment for the disease, vaccinations and COVID appropriate behavior have come to be the main approaches to combat the pandemic ...
Sruthi S +3 more
doaj +1 more source
, 2012 Objective: The objective of this study was to assess primary healthcare professionals' knowledge, attitude and behavior regarding immunization, as well as to evaluate the adverse effect profile for the 2006-2007 influenza ...
MISTIK, Selçuk +2 more
core +1 more source
Forest plot of adverse effect.
, 2023 Forest plot of adverse effect.
Yang Zhou (65942) +5 more
core +1 more source
Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin +17 more
wiley +1 more source
, 2013 Relationship between NER genes and general adverse events or grade 3/4 general adverse events profile (logistic regression).
Shengxiang Ren (300931) +7 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba +29 more
wiley +1 more source
Overview of adverse event profile during HAT therapy in published clinical trials.
, 2020 Overview of adverse event profile during HAT therapy in published clinical trials.
Andrea Kuemmerle (296573) +10 more
core +1 more source